According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion ...
In a recent review published in Genes & Diseases, researchers from Jinzhou Medical University, Technische Universität Dresden, and Helmholtz-Zentrum ...
Detailed price information for Gyre Therapeutics Inc (GYRE-Q) from The Globe and Mail including charting and trades.
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
A research team reports a promising new strategy: combining two already-approved drugs—silybin, a natural liver-protective compound, and carvedilol, a widely used cardiovascular medicine—to powerfully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results